Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

25 Sep 2023

TheraPsil Unveils MDMA-Assisted Psychotherapy Training Program

Non-profit TheraPsil announces launching of MDMA therapy training program....

By Microdose NewsDesk

Industry

22 Sep 2023

Cybin Completes Phase 2 Enrollment of CYB003 for Major Depressive Disorder

Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder....

By Microdose NewsDesk

Industry

21 Sep 2023

Seelos Therapeutics Announces Results from Phase II Depression Trial

Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide....

By Microdose NewsDesk

Industry

20 Sep 2023

Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

news

Don’t Miss

18 Sep 2023

News You Might Have Missed: Sep 18th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Finance

15 Sep 2023

Beckley Waves Raises $3.3 Million Funding Round

Beckley Waves raises $3.3 million, capital to be used for investing in startups focused on infrastructure and services for psychedelic therapies....

By Microdose NewsDesk
maps

Industry

14 Sep 2023

MAPS Publishes Results of Successful Phase 3 Trial

In big industry news, MAPS has published the second part of its long-awaited Phase 3 trial of MDMA-assisted therapy for PTSD....

By Microdose NewsDesk
Mindmed trial

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites....

By Microdose NewsDesk

Industry

11 Sep 2023

PurMinds Appoints Leading Drug Designer to Scientific Advisory Board

Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.